File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis

TitleChanges in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis
Authors
KeywordsComplications
Transforming Growth Factor β1
Radiation therapy
Issue Date1997
Citation
International Journal of Radiation Oncology Biology Physics, 1997, v. 37, n. 2, p. 253-258 How to Cite?
AbstractPurpose: To determine whether changes in the plasma Transforming Growth Factor β1 (TGFβ1) concentration during radiotherapy could identify patients at risk for developing symptomatic radiation pneumonitis. Methods and Materials: Thirty-six patients who received radiation therapy with curative intent for lung cancer (n = 31), Hodgkin's disease (n = 4), or thymoma (n = 1) were evaluated prospectively. All patients had serial plasma TGFβ1 measurements obtained before, during, and after treatment. Plasma TGFβ1 was quantified using an enzyme-linked immunosorbent assay. Pneumonitis was defined clinically. Plasma TGFβ1 levels were considered to have normalized if the following occurred: the last on-treatment TGFβ1 level was both <7.5 ng/ml and lower than the pretreatment level. Results: Thirteen of these 36 patients developed pneumonitis. Significant changes in plasma TGFβ1 levels during treatment were seen only in the subset of patients whose TGFβ1 levels were >7.5 ng/ml at baseline (n = 22). Failure of plasma TGFβ1 to normalize by the end of treatment, as defined above, much more accurately identified patients at risk for symptomatic pneumonitis if their baseline TGFβ1 was >7.5 ng/ml than if it was <7.5 ng/ml. Conclusions: Changes in plasma TGFβ1 levels during radiotherapy appears to be a useful means by which to identify patients at risk for the development of symptomatic radiation pneumonitis, particularly in the subset of patients whose pretreatment TGFβ1 levels are >7.5 ng/ml.
Persistent Identifierhttp://hdl.handle.net/10722/266760
ISSN
2023 Impact Factor: 6.4
2023 SCImago Journal Rankings: 1.992
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorAnscher, Mitchell S.-
dc.contributor.authorKong, Feng Ming-
dc.contributor.authorMarks, Lawrence B.-
dc.contributor.authorBentel, Gunilla C.-
dc.contributor.authorJirtle, Randy L.-
dc.date.accessioned2019-01-31T07:19:30Z-
dc.date.available2019-01-31T07:19:30Z-
dc.date.issued1997-
dc.identifier.citationInternational Journal of Radiation Oncology Biology Physics, 1997, v. 37, n. 2, p. 253-258-
dc.identifier.issn0360-3016-
dc.identifier.urihttp://hdl.handle.net/10722/266760-
dc.description.abstractPurpose: To determine whether changes in the plasma Transforming Growth Factor β1 (TGFβ1) concentration during radiotherapy could identify patients at risk for developing symptomatic radiation pneumonitis. Methods and Materials: Thirty-six patients who received radiation therapy with curative intent for lung cancer (n = 31), Hodgkin's disease (n = 4), or thymoma (n = 1) were evaluated prospectively. All patients had serial plasma TGFβ1 measurements obtained before, during, and after treatment. Plasma TGFβ1 was quantified using an enzyme-linked immunosorbent assay. Pneumonitis was defined clinically. Plasma TGFβ1 levels were considered to have normalized if the following occurred: the last on-treatment TGFβ1 level was both <7.5 ng/ml and lower than the pretreatment level. Results: Thirteen of these 36 patients developed pneumonitis. Significant changes in plasma TGFβ1 levels during treatment were seen only in the subset of patients whose TGFβ1 levels were >7.5 ng/ml at baseline (n = 22). Failure of plasma TGFβ1 to normalize by the end of treatment, as defined above, much more accurately identified patients at risk for symptomatic pneumonitis if their baseline TGFβ1 was >7.5 ng/ml than if it was <7.5 ng/ml. Conclusions: Changes in plasma TGFβ1 levels during radiotherapy appears to be a useful means by which to identify patients at risk for the development of symptomatic radiation pneumonitis, particularly in the subset of patients whose pretreatment TGFβ1 levels are >7.5 ng/ml.-
dc.languageeng-
dc.relation.ispartofInternational Journal of Radiation Oncology Biology Physics-
dc.subjectComplications-
dc.subjectTransforming Growth Factor β1-
dc.subjectRadiation therapy-
dc.titleChanges in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0360-3016(96)00529-9-
dc.identifier.pmid9069294-
dc.identifier.scopuseid_2-s2.0-0030978490-
dc.identifier.volume37-
dc.identifier.issue2-
dc.identifier.spage253-
dc.identifier.epage258-
dc.identifier.isiWOS:A1997WN99800003-
dc.identifier.issnl0360-3016-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats